Upload
byron-fields
View
217
Download
0
Embed Size (px)
Citation preview
Third Annual Maria Ricci Lecture Queen’s University and the
NCIC CTG Clinical Trials GroupKingston, Ontario
Canada
The Oxford Overview:
Is it Still Relevant in 2010 ?
Presented by
KATHLEEN I. PRITCHARD, MD, FRCPC
Sunnybrook Odette Cancer Centre
University of Toronto
Toronto, Canada
The Oxford Overview
Early Breast Cancer Trialists’ Collaborative Group
(EBCTCG)
EBCTCG OVERVIEWSteering Committee
K. Albain, S. Anderson, R. Arriagada, W. Barlow, J. Bergh, J. Bliss, M. Buyse, D. Cameron, M. Clarke, A. Coates, R. Collins, J. Costantino, J. Cuzick, S. Darby, N. Davidson, C. Davies, A. Di Leo, M. Dowsett, M. Ewertz, R. Gelber, C. Geyer, J. Godwin, A. Goldhirsch, R. Gray, D. Hayes, C. Hill, J. Ingle, R. Jakesz, M. Kaufmann, P. McGale, L. Norton, Y. Ohashi, S. Paik, E. Perez, R. Peto, M. Piccart, L. Pierce, G. Pruneri, K. Pritchard, V. Raina, P. Ravdin, J. Robertson, E. Rutgers, Y. F. Shao, S. Swain, C. Taylor, P. Valagussa, G. Viale, T. Whelan, E. Winer, Y. Wang, W. Wood.
EBCTCG OVERVIEWOxford Secretariat
Richard Peto
Sarah Darby
Mike Clarke
Christina Davies
Paul McGale
Richard Gray
Rory Collins
Jon Godwin
EBCTCG OVERVIEWSteering Committee - Executive
Marc Buyse
Mike Clarke
Rory Collins
Sarah Darby
Christina Davies
Marianne Ewertz
Martine Piccart
Kathy Pritchard
Eric Winer
William Wood
EBCTCG OVERVIEW
Past Chairs
I. Craig Henderson
William Wood
Current Co-Chairs
Kathy Pritchard
Martine Piccart
EBCTCG September 2010. Preliminary results
EBCTCG OVERVIEW1984
First overview process
data sought from all randomized
trials of systemic adjuvant therapy
meta-analysis concept
collaboration sought built
sustained
Trialists
Secretariat
EBCTCG OVERVIEW
Methodology
Individual patient data
dates of randomization
treatment allocation
age
menopausal status
nodes
ER, PgR
EBCTCG OVERVIEW
Methodology
Data checked for internal consistency
Data amended and updated by
correspondence
EBCTCG OVERVIEWMethodology
Each trial analysed separately
Women in one trial are compared directly with only the women in the same trial
One log rank statistic per trial
Stratified by age and nodal status
Combined to give an overall estimate ofthe effect of different treatments
EBCTCG OVERVIEW
Outcomes
Recurrence
first reappearance of breast cancer
includes contralateral breast cancer
EBCTCG OVERVIEW
Outcomes
Deaths
unknown causes included with deaths from breast cancer unless specifically stated otherwise
problem of death without recurrence
EBCTCG OVERVIEW
Outcomes
Breast Cancer Related Deaths
deaths of/with breast cancer
EBCTCG OVERVIEW
Outcomes
Other Deaths
cardiac
stroke
other cancers
EBCTCG OVERVIEW
1984
Tamoxifen improved survival
CMF chemotherapy improved survival
Ovarian ablation improved survival
EBCTCG OVERVIEW
1990
longer tamoxifen seemed better
tamoxifen effects greater in ER+ve
women
tamoxifen reduced rate of contralateral breast cancer
chemo effective in older and younger women
EBCTCG OVERVIEW
1995
huge magnitude of effect of 5 years of tamoxifen
5 years of tamoxifen clearly better than 1 or 2
tamoxifen prevented contralateral
breast cancer only in women with ER+ve disease
anthracycline containing regimens better than CMF
EBCTCG OVERVIEW
2000
15 year effects of chemo sustained in older and younger women
chemo effect appears greater in ER negative
than in ER positive disease
But is this really true?
EBCTCG OVERVIEW
2000
15 year effects of 5 years of tamoxifen sustained and of great magnitude
door opened to question of 5 years versus
longer tamoxifen
ovarian suppression/ablation effective but not significantly so when added to chemotherapy
EBCTG OVERVIEW
2005
2000 Overview: Lancet, 2005 Trialists meet: new Steering Committee
formed Many new trials added More women-years of follow-up for all major
questions But major trials still missing
EBCTCG OVERVIEW2006 Trialists met: new questions
type of anthracycline-based regimen taxane trial status
aromatase inhibitors trastuzumab
chemoendocrine therapy (only in ER+, pre- and postmenopausal subsets) Subcommittees of the SC formed
EBCTCG OVERVIEW2010
Tamoxifen
AI’s
Chemotherapy
Locoregional therapy
2010 EBCTCG OVERVIEWTAMOXIFEN
TAMOXIFEN VS NOT LONGER VS SHORTER TAMNo of women No of women
1 yr vs not2 yr vs not
5 yr vs not
91262394021457
2 – 4 vs 1 – 2 y 5 vs 1 - 2 y
10 vs 5 y
32002000022000
54523 45200
Median follow-up = 15y22% are ER- PR-
Median follow-up = 5y50% are ER ?
2010 EBCTCG OVERVIEWTamoxifen for 5y vs same management but No Tam
Benefits(ER+)
Risks(all)
Proportional risk reductions• Recurrence 38% (2p<0.00001)•BC mortality 30% (2p<0.00001)• All deaths 22% (2p<0.00001)
• Contralateral BC 39% (2p<0.00001)
Death w/o recurrence * RR 1.05 (+ 0.07) 2p>0.1
Endometrial incidence RR 2.33 (+ 0.25)
2p<0.00001
* Numerical excess of deaths due to stroke, pulmonary embolus, uterine cancer(15 vs 13 ; 6 vs 0; 8 vs 1)
Absolute gainat 15y
13%9%
2010 EBCTCG OVERVIEWTamoxifen for 5y vs same management but no Tam
Learning more about Tam benefits
On types of B.C. events…
In subgroups
In relation to chemotherapy administration
Over time…
2010 EBCTCG OVERVIEWTamoxifen for 5y : Impact on BC events
2010 EBCTCG OVERVIEWTamoxifen for 5y: Benefits in subgroups
2010 EBCTCG OVERVIEWTamoxifen for 5y vs same management but no Tam
TAM for5y :
BENEFITSfor whom ?
AGE
Nodal status
Tumor grade
Tumor diameter
2010 EBCTCG OVERVIEWTamoxifen for 5y : Benefits in subgroups
All do benefit !!
2010EBCTCG
OVERVIEW
2010EBCTCG
OVERVIEW
2010 EBCTCG OVERVIEWTamoxifen for 5y: Benefits in subgroups
TAM for5y :
BENEFITSfor whom ?
ER levels(fmol/mg prot)
ER- PR-
ER- PR+
ER+ PR+
ER+ PR-
No
Uncertain
Yes
Yes
2010 EBCTCG OVERVIEWTamoxifen for 5y : Benefit over time
2010 EBCTCG OVERVIEW
Duration of adjuvant Tam and outcome
2010 EBCTCG OVERVIEWImpact of TAM duration
Even 1y onlyprovides
significantbenefit
10y providesmall benefit
which could ↑ over time
2010 EBCTCG OVERVIEWTamoxifen for 10y : Benefits vs risks at 10 y
Mean follow-up only 5y
Benefits Risks
Proportional risk reductions• Recurrence 8% (2p=0.03)• BC mortality 3% (2p>0.1)• Contralateral BC
Death w/o recurrence * + 1,5% (2p=0.59) Endometrial cancers + 0.7% (2p=0.00004)
*Numerical excess of deaths due to cerebrovascular events (42 vs 38 in y0-4; 27 vs 24 in y5-10), thrombo-embolic events (10 vs 56 in y0-4), end. cancers
(8 vs 6 in y0-4, 4 vs 2 in y5-10)
Absolute gain
1% (2p 0.03)2,9% (2p 0.55)1.3% (2p 0.03)
Absolute Xcess
2010 EBCTCG OVERVIEWTAMOXIFEN
5y in ER+ disease
reduces recurrence by 38%, BC death by 30%
all deaths by 22% contralateral BC by 40%
benefits all women with ER+ disease unclear benefits in ER-PgR+ disease
benefits women with ER very rich tumors more increases endometrial cancer by 2.3 fold
2010 EBCTCG OVERVIEWTAMOXIFEN
10 yrs vs 5 yrs of adjuvant TAMOXIFEN in ER+/? Disease
absolute reduction in recurrence by 1% (2p=0.03) reduces contralateral BC by 1.3% (2p=0.03) increases endometrial cancer by 0.7% (2p=0.00004) reduces BC mortality by 3% (2p=0.55) increases death without recurrence by 1.5% (2p=0.59)
2010 EBCTCG OVERVIEWTAMOXIFEN
Messages for clinical practice in 2010
PgR does not predict for benefit of adjuvant TAM For ER-PgR+ patients, the tumor should be retested and if doubt remains, TAM could be offered There is presently little incentive to prescribe more than 5y of TAM, especially in women with an uterus
EBCTCG SEPTEMBER 2010
Aromatase inhibitors
Data from 1st analysis
• No unplanned cross-over
• Cut-off 30 Sept 2006
• Cohort 1: 5yrs AI vs 5yrs tam
• Cohort 2: 2-3 yrs of AI vs 2-3 yrs of tamafter 2-3 yrs tam
JCO, 2010, 28, 509-518
5 years AI vs tamoxifen: trial-specific recurrence data
JCO, 2010, 28, 509-518
5 years AI vs tamoxifen: life table curve, recurrence
JCO, 2010, 28, 509-518
5 years AI vs tamoxifen: life table curves, br ca mortality
JCO, 2010, 28, 509-518
2-3yr AI vs tam after 2-3 yrs tam: life table curve, recurrence
JCO, 2010, 28, 509-518
2-3yr AI vs tam after 2-3 yrs tam: life table curve, br ca mortality
JCO, 2010, 28, 509-518
2-3yr AI vs tam after 2-3 yrs tam: life table curve, mortality(C) without recurrence, (D) all cause
2010 EBCTCG OVERVIEWAromatase Inhibitors
Message for Clinical Practice in 2010
AIs > tamoxifen
recurrence
survival
good given
early
after 2 yrs
N ≈ 10.000N ≈ 14000
2010 EBCTCG OVERVIEWCHEMOTHERAPY
Polychemo vs NOT Anthracycline (A) vs CMF Taxane (+A) vs A
N = 23500 N = 22000 N = 44000
N ≈ 9500N ≈ 18000
N ≈ 23.000
N ≈ 11.000
CMF vs NOT(only 5000 st CMF)
Anthrac vs NOT(only 3000 of Mas strenght)
Anthrac vs st CMF
Tax + A vs lots of ATax + A vs more ATax + A vs same A
2010 EBCTCG OVERVIEW
Polychemotherapy versus
No chemotherapy
10y results in 23500 women
2010 EBCTCG OVERVIEWPolychemotherapy vs NIL : 10y results
ANTHRACYCLINE
CMF
STANDARDS
2010 EBCTCG OVERVIEWPolychemotherapy vs NO CTX : 10y results
Anthracycline vs No CTX CMF vs No CTX
RR
1.0
0.5
0.680.76 0.720.73
0.82 0.79
RR
1.0
0.5
0.700.80 0.76 0.76
0.88 0.84
Recurrence BC mortality Recurrence BC mortality
A≥60E≥90
Lowerdoses
All A≥60E≥90
Lowerdoses
All St CMF
otherCMF
AllSt
CMFotherCMF
All
2010 EBCTCG OVERVIEWPolychemotherapy vs NIL
Learning more about benefits
• Over time...
• In subgroups
2010 EBCTCG OVERVIEWPolychemotherapy vs NO CTX :
Impact over time
Anthracycline vs No CTX CMF vs No CTX
Strong, early effect... !
2010 EBCTCG OVERVIEWPolychemotherapy vs NO CTX :
Impact on recurrence in subgroups
Anthracycline vs NO CTX Standard CMF vs NO CTX
No indication of reduced benefit !
No indication of reduced benefit !
Tumour
diameter
PolyCTX vsNo CTX
Who benefits ?
Tumour
Grade
AGE
ER poor,
+ or ?
Concurrent
endocrine
therapy
Nodal
Status
2010 EBCTCG OVERVIEWPolychemotherapy vs NO CTX :
Benefits in subgroups
All do benefit !
2010 EBCTCG OVERVIEW
Anthracycline regimens
vs
standard CMF
10y results in 22000 women
AC X4
ANTHRACYCLINE
MORE
2010 EBCTCG OVERVIEW
0.5
1.0
2010 EBCTCG OVERVIEWAnthracycline vs standard CMF :
10 y results mortality with recurrence Ratio ofannualdeathrates
0.89 0.89
0.780.82
0.980.93
Any Aregimen
CumdoseA 360
E 720-800
CumdoseA 300
E 400-480
Cumdose
A ≤ 360
Dose per cycle< A60, E90
Dose per cycle ≥ A60, E90
2010 EBCTCG OVERVIEW
Taxane + Anthracycline regimens vs
Anthracycline regimens
5y results in 44000 women
2010 EBCTCG OVERVIEW
T+AVssameA
T+AVsmoreA
0.75
1.0
2010 EBCTCG OVERVIEWTaxane + Anthracycline vs A :5 y results in 44000 women
Recurrence Mortality w/recurrence
Ratio ofannualeventrates
allT+Avs
same AT+Avs
more A
T+Avs
int A
T+Avs
int A
T+Avs
more A
T+Avs
same Aall
2p<0.000012p=0.00012p<0.0001 2pNS 2p=0.000012p=0.001 2p=0.003 2pNS
2010 EBCTCG OVERVIEW:Polychemotherapy :
Impact on recurrence over time
Anthracycline vs st CMF Anthracycline (A) + Taxane vs A
EARLY IMPACT EARLY and LATE IMPACT
2010 EBCTCG OVERVIEWTaxane + Anthracycline vs A :
Impact on recurrence in subgroups
No indication of reduced benefit !
2010 EBCTCG OVERVIEWPOLYCHEMOTHERAPY
Messages for clinical practice in 2010
Taxane-based regimens
Reduced in recurrence (2.8%)
Reduced mortality with recurrence (1.3%) Except when compared to very well dosed (total 2x2) anthracycline-based regimens
Effect seems independent from the recorded tumor characteristics (with lack on information
on HER2)
Effect persists over 5 years
Effect of Radiotherapy after Breast-conserving Surgery on
10-year Recurrence and 15-year Mortality
in Women with Early Breast Cancer
EBCTCG September 2010. Preliminary results
EBCTCG September 2010. Preliminary results
Randomised trials of radiotherapy following breast-conserving surgery (BCS ± RT)
that began before the year 2000
Trial category No of trials
Years trials
started No of women
Lumpectomy 6 1976-86 4500 Sector resection 4 1981-91 2400 Low risk women 7 1989-96 4000 All women 17 11,000 pN0 7300 pN+ 1100 pN ? 2500
50% increase since EBCTCG (2005)
EBCTCG September 2010. Preliminary results
Proportional effect of radiotherapy after breast-conserving surgery (BCS ± RT) 11 000 women, pN0/pN+/pN?
Any recurrence Breast cancer mortality
EBCTCG September 2010. Preliminary results
Absolute effect of radiotherapy after breast conserving surgery (BCS ± RT): 11 000 women pN0/pN+/pN?
Any recurrence Breast cancer mortality Any death
EBCTCG September 2010. Preliminary results
Effect of radiotherapy after breast-conserving surgery (BCS ± RT): 1100 pN+ women
Any recurrence Breast cancer mortality
“One-in-four rule” one breast cancer death avoided for every 4 recurrences avoided
EBCTCG September 2010. Preliminary results
Absolute effect of radiotherapy after breast-conserving surgery (BCS ± RT): 7300 pN0 women
Any recurrence Breast cancer mortality
“One-in-four rule” one breast cancer death avoided for every 4 recurrences avoided
Conclusions
• Radiotherapy highly effective in reducing recurrence in both pN0 and pN+ women
• Radiotherapy also reduces 15-year breast cancer
• “One-in-four” rule applies for pN0 and pN1 women
• Benefits not substantially reduced by fatal side-effects
EBCTCG September 2010. Preliminary results
The Oxford Overview:
Is it Still Relevant in 2010 ?
YES
EBCTCG OVERVIEW
Tamoxifen
5 +/- 5 years
30% - 40% in recurrence
25 in deaths
EBCTCG OVERVIEW
AIs
Better than Tam
for all subgroups
25% in recurrence
0 – 25% in BC mortality
EBCTCG OVERVIEW
AIs
? Stronger effect after two
years of tamoxifen
EBCTCG OVERVIEW
Chemotherapy vs None
CMF/AC
20 – 30% recurrence
10 – 30% BC mortality
A vs CMF
EBCTCG OVERVIEW
Adriamycin vs Standard CMF
10 – 20% recurrence
10 – 20% mortality
EBCTCG OVERVIEW
Taxanes vs Non-Taxanes
10 – 20% recurrence
10% BC mortality
EBCTCG OVERVIEW
Natural History of Breast Cancer
ER/PgR +ve
ER and PgR -ve
EBCTCG OVERVIEW
By having all data
avoids publication bias
gives average effect size
clarifies time frames of effects
process / outcomes both useful
EBCTCG OVERVIEW
Future – Yes
Publications
3 on radiation results
2010 - 2011
one on chemotherapy
2011
one on AIs
2011
Meet Again September 19-22, 2012
EBCTCG OVERVIEW
Future – Yes
Publications
3 on radiation results
2010 - 2011
one on chemotherapy
2011
one on AIs
2011
Meet Again September 19-22, 2012